Arcturus Therapeutics

Arcturus Therapeutics News & Events

Arcturus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., as Chief Business Officer

October 28, 2013

FOR IMMEDIATE RELEASE SAN DIEGO, Calif., October 28, 2013 – Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treatment of rare orphan diseases, today announced the expansion of its management team with the appointment of Zachary A. Zimmerman, Ph.D., as chief business officer. Dr. Zimmerman will be responsible for defining Arcturus’ corporate […]

Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014

October 21, 2013

FOR IMMEDIATE RELEASE SAN DIEGO, Calif., October 21, 2013 – Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treatment of rare orphan diseases, today announced it has secured $5 million in a Series A funding round led by multiple private capital, high net-worth investors from Canada, Japan and the United States. The […]

Arbutus obtained a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleomonomer Agent (UNA) from Arcturus.

October 1, 2013

In 2012, Arbutus obtained a worldwide, non-exclusive license to a novel RNAi trigger technology called Unlocked Nucleobase Analog (UNA) from Marina Biotech for the development of RNAi therapeutics. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects. Read more about RNA Trigger […]